Descriptive cross-sectional study to assess the diagnostic and prognostic value of whole-body MRI with diffusion and 18F-FDG-PET/CT in patients with multiple myeloma

Abstract

Background. Multiple myeloma (MM) is the second most frequent hematologic cancer, after Non-Hodgkin Lymphoma. Like most blood cancers, complete remission is a difficult task to achieve, therefore, prognostic factors such as treatment response and minimal residual disease (MRD) are important points to be assessed.The most sensitive imaging technique to diagnose MM is Whole-Body MRI with diffusion using MY-RADS protocol. The most specific test to assess minimal residual disease is 18F-FDG-PET/CT using IMPeTUs guide. Since these are two different techniques, the pre-treatment acquisition with MRI, and the follow-up and post-treatment acquisition with PET/CT, cannot be compared. Objective. To evaluate the sensitivity, specificity and predictive values of WB-MRI-DWI and 18F-FDG-PET/CT to diagnose and evaluate treatment response and MRD in patients with symptomatic Multiple Myeloma. Methods. This protocol consists of a descriptive cross-sectional study in patients with symptomatic MM to whom WB-MRI-DWI and 18F-PET/CT will be performed to diagnose, to see the treatment response at the middle of the therapy and at the end of the therapy, and to assess MRD